Veraxa Biotech Ag logo

Veraxa Biotech Ag(NASDAQ) VRXAW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-87%
5 YearN/A
1 YearN/A
1 Month-67%
$0.03
+0.00%
+0.00Today
Veraxa Biotech Ag last closing stock price
MetricPriceDate
Last closeUSD 0.032026-10-13
Veraxa Biotech Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.34%USD 0.032026-10-06
1 month-67.28%USD 0.102026-09-10
3 month-73.72%USD 0.122026-07-15
Since inception-87.33%USD 0.252026-06-11

Veraxa Biotech Ag Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

5.42 (High)

Price

$0.03

Volume

20,000

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.03 - $0.35

Estimated Earnings Date

N/A

VRXAW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Veraxa Biotech Ag

Veraxa Biotech AG is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based cancer therapies. The company leverages scientific breakthroughs from the European Molecular Biology Laboratory to advance its drug discovery and development engine.

Products and Services
  • Specializes in antibody-drug conjugates (ADCs) for cancer treatment
  • Develops novel antibody-based therapy concepts
  • Engages in drug discovery and development initiatives
Growth Outlook
  • Market demand for innovative cancer therapies is increasing
  • Strong pipeline of next-generation antibody therapies under development
  • Potential partnerships with larger biopharmaceutical companies
Financial Highlights
  • Market capitalization stands at approximately $1.87 million
  • Recent stock price range between $0.0741 and $0.0808
  • Beta of 0.599 indicates lower volatility compared to the market
Veraxa Biotech AG operates in the dynamic biotechnology sector, focusing on innovative cancer therapies that address significant unmet medical needs. The company's commitment to advancing antibody-based treatments positions it well within a growing market. With a solid foundation based on scientific research, Veraxa is poised for potential growth through strategic partnerships and a robust pipeline of products. The financial metrics indicate a stable market presence, with a relatively low beta suggesting less volatility compared to broader market trends. Investors may find Veraxa Biotech AG an intriguing opportunity in the biopharmaceutical landscape.
AI Generated • Sep 23, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Heidelberg, ZH 69120, DE

VRXAW Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

20.00K

Avg. Volume

47.33K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Veraxa Biotech Ag Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,721.68+0.00%
^DJIDJI
$52,076.17+0.01%
^IXICNASDAQ
$26,579.10-0.00%
BTCBitcoin
$82,037.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.63-0.13%
INTCIntel
$95.37-2.80%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
CRWVCoreWeave
$69.69+5.94%

Questions About VRXAW

What is the current price of Veraxa Biotech Ag?

Veraxa Biotech Ag is trading at $0.03 per share.

What is the 52-week range for Veraxa Biotech Ag?

Over the past 52 weeks, Veraxa Biotech Ag has traded between $0.03 and $0.35.

How much debt does Veraxa Biotech Ag have?

Veraxa Biotech Ag total debt is unavailable.

How much cash does Veraxa Biotech Ag have on hand?

Veraxa Biotech Ag does not have cash on hand data available.

What is Veraxa Biotech Ag’s dividend yield?

Veraxa Biotech Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services